MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Innoviva Inc

Gesloten

SectorGezondheidszorg

19.58 -1.56

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.26

Max

19.88

Belangrijke statistieken

By Trading Economics

Inkomsten

-67M

-47M

Verkoop

-3.2M

89M

K/W

Sectorgemiddelde

51.694

39.857

Winstmarge

-52.559

Werknemers

127

EBITDA

-63M

-27M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+102.87% upside

Dividenden

By Dow Jones

Volgende Winsten

29 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

53M

1.2B

Vorige openingsprijs

21.14

Vorige sluitingsprijs

19.58

Nieuwssentiment

By Acuity

60%

40%

323 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Innoviva Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 jul 2025, 23:34 UTC

Acquisities, Fusies, Overnames

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 jul 2025, 21:14 UTC

Acquisities, Fusies, Overnames

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 jul 2025, 21:04 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 jul 2025, 23:43 UTC

Marktinformatie

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 jul 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 jul 2025, 22:47 UTC

Acquisities, Fusies, Overnames

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 jul 2025, 22:46 UTC

Acquisities, Fusies, Overnames

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 jul 2025, 22:46 UTC

Acquisities, Fusies, Overnames

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 jul 2025, 22:43 UTC

Acquisities, Fusies, Overnames

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 jul 2025, 22:43 UTC

Acquisities, Fusies, Overnames

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 jul 2025, 22:40 UTC

Acquisities, Fusies, Overnames

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:40 UTC

Acquisities, Fusies, Overnames

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:30 UTC

Marktinformatie
Winsten

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 jul 2025, 22:20 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

17 jul 2025, 22:20 UTC

Marktinformatie
Winsten

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 jul 2025, 22:04 UTC

Marktinformatie
Winsten

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 jul 2025, 22:03 UTC

Acquisities, Fusies, Overnames

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 jul 2025, 21:58 UTC

Marktinformatie
Winsten

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 jul 2025, 21:57 UTC

Winsten

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:47 UTC

Winsten

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 jul 2025, 21:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 jul 2025, 21:45 UTC

Marktinformatie

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 jul 2025, 21:38 UTC

Acquisities, Fusies, Overnames

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 jul 2025, 21:22 UTC

Acquisities, Fusies, Overnames

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 21:05 UTC

Winsten

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:04 UTC

Acquisities, Fusies, Overnames

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 jul 2025, 21:02 UTC

Acquisities, Fusies, Overnames

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 20:59 UTC

Acquisities, Fusies, Overnames

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

17 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Innoviva Inc Prognose

Koersdoel

By TipRanks

102.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 40.33 USD  102.87%

Hoogste 55 USD

Laagste 26 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Innoviva Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

18.57 / 18.75Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

323 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.